Reactivation of overt or occult HBV infection (HBVr) is a well-known, potentially life-
threatening event which can occur during the course of immunosuppressive treatments …

Abstract With a 5.3% of the global population involved, hepatitis B virus (HBV) is a major
public health challenge requiring an urgent response. After a possible acute phase, the …

It is well known that immunosuppressive drugs or cancer chemotherapy can stimulate
replication of hepatitis B virus (HBV) and precipitate severe flares of HBV infection. The risk …

Results It was found that the positive hepatitis B surface antigen (HBsAg), the high baseline
HBV DNA level, the positive hepatitis B virus e antigen (HBeAg), and an absent or low …

It is well known that hepatitis B virus reactivation (HBVr) can occur among patients
undergoing treatment for hematological malignancies (HM). The evaluation of HBVr risk in …

Hepatitis B virus (HBV) reactivation (HBVr) in patients undergoing immunosuppressive
therapy is still a hot topic worldwide. Its prevention and management still represents a …

Hepatitis B virus (HBV) reactivation can lead to severe acute hepatic failure and death in
patients with HBV infection. HBV reactivation (HBVr) most commonly develops in patients …

Abstract Hepatitis B (HBV) reactivation (HBVr) is a potentially fatal complication in patients
with past HBV exposure receiving immunosuppressive therapy. HBVr can occur in patients …

Hepatitis B virus reactivation (HBVr) is an important complication of immunosuppressive
drug therapy (ISDT). It can occur with active or resolved hepatitis B virus (HBV) infection with …

Hepatitis B virus (HBV) reactivation in the setting of immunosuppressive therapy is an
increasingly recognized and preventable cause of elevated liver enzymes and clinical …